STOCK TITAN

[Form 3] RedHill Biopharma Ltd. Initial Statement of Beneficial Ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

RedHill Biopharma Ltd. executive Guy Joel Goldberg filed a Form 3 reporting his initial ownership in the company. He directly holds American Depositary Shares and Ordinary Shares, including 30,572 unvested restricted share units, each tied to one ADS that represents 10,000 Ordinary Shares. He also holds fully vested stock options to purchase 250,000, 450,000, 370,000 and 600,000 Ordinary Shares at exercise prices of $5,000, $4,870, $5,000 and $7,080 per ADS, expiring between 2028 and 2031.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Goldberg Guy Joel

(Last)(First)(Middle)
21 HA'ARBA'A STREET

(Street)
TEL AVIV6473921

(City)(State)(Zip)

ISRAEL

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
RedHill Biopharma Ltd. [ RDHL ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares305,720,000(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
American Depositary Shares (2) (2)Ordinary Shares555,310,000(2)D
Stock Option (Right to Buy) (3) (3)Ordinary Shares250,000(3)D
Stock Option (Right to Buy) (4) (4)Ordinary Shares450,000(4)D
Stock Option (Right to Buy) (5) (5)Ordinary Shares370,000(5)D
Stock Option (Right to Buy) (6) (6)Ordinary Shares600,000(6)D
Explanation of Responses:
1. Represents 30,572 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.
2. Represents 5,531 ADSs, which are convertible at any time, at the holder's election and have no expiration date.
3. Represents stock option to purchase 250,000 Ordinary Shares (equivalent to 25 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on 3/21/2028.
4. Represents stock option to purchase 450,000 Ordinary Shares (equivalent to 45 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on 3/25/2030.
5. Represents stock option to purchase 370,000 Ordinary Shares (equivalent to 37 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on 5/06/2029.
6. Represents stock option to purchase 600,000 Ordinary Shares (equivalent to 60 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on 4/28/2031.
/s/Guy Goldberg03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)
Redhill Biopharm

NASDAQ:RDHL

View RDHL Stock Overview

RDHL Rankings

RDHL Latest News

RDHL Latest SEC Filings

RDHL Stock Data

4.36M
5.11M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Tel Aviv-Yafo